Rising incidence of alopecia across the globe is expected to drive the market growth in the coming years. Increasing awareness about various treatment options and technological advancements in the field of dermatology are also contributing to the growth of the market. Moreover, the availability of novel therapies and increasing healthcare expenditure are further fueling the market growth.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Disease Type, Treatment, Gender, Sales Channel, Ed-Use |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Janssen Global Services, Cipla Limited, Merck & Co.,, GlaxoSmithKline plc, Sun Pharmaceuticals Industries, Dr. Reddy’s Laboratories, Aurobindo Pharma, Viatris, Pfizer,, Lilly, Lexington Intl., LLC, Freedom Laser Therapy, Curallux, LLC., Apira Science, Revian, Theradome, Lutronic |
High cost associated with the treatment of alopecia is A primary hindrance hindering the market growth. Limited reimbursement policies and lack of skilled healthcare professionals in some regions are also posing challenges to the market growth. Additionally, side effects associated with certain treatment options are a major concern for both patients and healthcare providers.